Roberts Sacha, Rojas Aram, Gachabayov Mahir, Castaldi Maria
Department of Surgery, Westchester Medical Center, New York Medical College School of Medicine, Valhalla, NY, United States.
Int J Surg Protoc. 2020 Nov 5;24:36-38. doi: 10.1016/j.isjp.2020.10.003. eCollection 2020.
In COVID-19 pandemic epicenters cancer care was severely impacted. All elective and semi-elective procedures, as well as select urgent cases, were postponed in order to preserve resources and protect patients and staff from SARS-CoV-2 exposure. Structured decision making for breast cancer treatment resulted in deferment of surgery with initiation of endocrine therapy. Moreover, the waitlist for elective breast cancer procedures after mitigation is a challenge for prioritization.
We aim to summarize the current body of evidence, comparatively evaluate oncological outcomes of surgery versus primary endocrine therapy (PET), and determine whether PET is a viable longterm alternative to surgery in the context of crisis management strategy for early, operable hormone receptor positive (HRP) breast cancer. PET could potentially be an acceptable bridging or maintenance therapy in select patients during pandemic crisis or for those choosing to forgo surgery in the treatment of breast cancer.
The database search includes PubMed, EMBASE, and MEDLINE (via Ovid). This systematic review includes women 18 years or older undergoing one of two interventions for HRP breast cancer: surgery (with or without endocrine therapy post-surgery) or solely PET. Studies comparing one of the two interventions of interest to a non-relevant intervention and studies reporting only descriptive data will not be included in the quantitative synthesis of data. After selection of eligible studies based on title and abstract, these studies will be further screened through full text articles by two independent reviewers, with a third as an arbitrator. Eligible studies will be critically appraised at the study level for methodological quality. Cochrane methodology will be utilized for meta-analysis.
This study does not require an institutional review board approval given its summary design nature. Findings of this systematic review will be published in a peer-reviewed journal.
在新冠疫情的中心地区,癌症护理受到了严重影响。为了保存资源并保护患者及医护人员免受严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染,所有择期和半择期手术以及部分紧急病例都被推迟。乳腺癌治疗的结构化决策导致手术推迟并开始内分泌治疗。此外,缓解措施实施后择期乳腺癌手术的等待名单在确定优先顺序方面是一项挑战。
我们旨在总结当前的证据,比较评估手术与初始内分泌治疗(PET)的肿瘤学结局,并确定在早期可手术的激素受体阳性(HRP)乳腺癌危机管理策略背景下,PET是否是手术可行的长期替代方案。在大流行危机期间,PET可能是某些患者可接受的过渡或维持治疗,或者对于那些选择放弃手术治疗乳腺癌的患者也是如此。
数据库检索包括PubMed、EMBASE和MEDLINE(通过Ovid)。这项系统评价纳入18岁及以上接受HRP乳腺癌两种干预措施之一的女性:手术(术后有或无内分泌治疗)或单纯PET。将感兴趣的两种干预措施之一与不相关干预措施进行比较的研究以及仅报告描述性数据的研究将不纳入数据的定量综合分析。根据标题和摘要选择符合条件的研究后,这些研究将由两名独立审稿人通过全文进行进一步筛选,第三名审稿人作为仲裁者。符合条件的研究将在研究层面进行方法学质量的严格评估。将采用Cochrane方法进行荟萃分析。
鉴于本研究的综述设计性质,无需机构审查委员会批准。本系统评价的结果将发表在同行评审期刊上。